Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 symbols : NVO save search
Novo Nordisk A/S: Phase 3 data for concizumab show 86% reduction in treated bleeds in haemophilia A or B with inhibitors
Published: 2022-07-10 (Crawled : 16:20) - globenewswire.com
NVO | News | $125.45 -2.48% 1.8M
|
Health Technology
| Email alert
Add to watchlist
haemophilia phase 3
Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca
Published: 2022-04-29 (Crawled : 11:00) - biospace.com/
SNYNF | News | $94.25 480
|
Health Technology
|
| O: 0.48%
H: 0.24%
C: 0.24%
NVO | News | $125.45 -2.48% 1.8M
|
Health Technology
|
| O: 5.98%
H: 1.44%
C: -0.42%
SNY | News | $46.615 -2.25% 730K
|
Health Technology
|
| O: 1.93%
H: 0.0%
C: 0.0%
IPHA | $2.37 170
|
Health Technology
|
| O: 11.11%
H: 3.67%
C: -4.33%
AZN | News | $71.26 0.58% 3.8M
|
Health Technology
|
| O: 0.53%
H: 2.37%
C: 0.26%
trial payment cancer phase 3
Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-07-21 (Crawled : 13:00) - biospace.com/
NVO | News | $125.45 -2.48% 1.8M
|
Health Technology
|
| O: 0.9%
H: 0.72%
C: 0.58%
LLY | News | $731.81 -1.86% 1M
|
Health Technology
|
| O: 0.58%
H: 0.42%
C: 0.38%
ALNY | $144.52 -1.06% 140K
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -2.13%
disease liver disease treatment phase 1 results liver trial phase 2 phase 3
Investigational 2 mg Dose of Ozempic® (semaglutide) Injection Demonstrates Superior Reductions in Blood Sugar vs Ozempic® 1 mg in Adults With Type 2 Diabetes in a Phase 3 Trial
Published: 2021-06-26 (Crawled : 04:20) - prnewswire.com
NVO | News | $125.45 -2.48% 1.8M
|
Health Technology
| Email alert
Add to watchlist
diabetes blood injection phase 3 trial
Investigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial
Published: 2021-06-26 (Crawled : 04:20) - globenewswire.com
NVO | News | $125.45 -2.48% 1.8M
|
Health Technology
| Email alert
Add to watchlist
diabetes blood phase 3 trial
Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide
Published: 2021-04-21 (Crawled : 14:00) - globenewswire.com
NVO | News | $125.45 -2.48% 1.8M
|
Health Technology
|
| O: 0.4%
H: 1.1%
C: 0.9%
obesity ev phase 3
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
CZOO | $10.52 110.82% 10M
|
CSSE 4 | $0.3181 108.86% 170M
|
Consumer Services
BOF | $1.88 60.68% 98M
|
AMST | $3.1 55.0% 66M
|
Technology Services
LICN | $0.8592 53.43% 13M
|
WIMI | $1.03 41.99% 15M
|
Technology Services
MULN | News | $3.675 34.62% 11M
|
Information
RILY | $28.605 31.7% 9.9M
|
Finance
RBBN 4 | $3.305 28.6% 1.9M
|
Electronic Technology
RCAT | $1.53 27.5% 2.9M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.